8.25
1.79%
-0.15
アフターアワーズ:
8.73
0.48
+5.82%
前日終値:
$8.40
開ける:
$8.28
24時間の取引高:
315.02K
Relative Volume:
3.41
時価総額:
$262.73M
収益:
$193.67M
当期純損益:
$4.82M
株価収益率:
17.93
EPS:
0.46
ネットキャッシュフロー:
$15.53M
1週間 パフォーマンス:
+1.35%
1か月 パフォーマンス:
+4.96%
6か月 パフォーマンス:
-10.13%
1年 パフォーマンス:
-21.13%
Zynex Inc Stock (ZYXI) Company Profile
ZYXI を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
9.30 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.72 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
0.1402 | 295.87M | 2.07B | -1.42B | -1.37B | -0.6765 |
MOBBW
Mobilicom Limited Warrants
|
0.6475 | 278.60M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.32 | 142.97M | 0 | 0 | 0 | 0.00 |
JUNE
Dhandho Junoon Etf
|
4.01 | 52.16M | 0 | 0 | 0 | 0.00 |
Zynex Inc Stock (ZYXI) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-10-16 | 開始されました | RBC Capital Mkts | Outperform |
2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-02-28 | 繰り返されました | B. Riley Securities | Buy |
2021-07-16 | アップグレード | B. Riley Securities | Neutral → Buy |
2021-03-09 | アップグレード | Northland Capital | Market Perform → Outperform |
2021-02-26 | ダウングレード | B. Riley Securities | Buy → Neutral |
2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-01-28 | ダウングレード | Northland Capital | Outperform → Market Perform |
2020-09-14 | アップグレード | H.C. Wainwright | Neutral → Buy |
2020-09-09 | アップグレード | Northland Capital | Market Perform → Outperform |
2020-07-29 | アップグレード | B. Riley FBR | Neutral → Buy |
2020-07-20 | 開始されました | Piper Sandler | Overweight |
2020-07-13 | ダウングレード | B. Riley FBR | Buy → Neutral |
2020-07-10 | 繰り返されました | H.C. Wainwright | Neutral |
2020-06-16 | ダウングレード | Northland Capital | Outperform → Market Perform |
2020-05-19 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2020-04-01 | 開始されました | Northland Capital | Outperform |
2019-09-23 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Zynex Inc (ZYXI) 最新ニュース
Electrotherapy System Market Future Business Opportunities - openPR
How to Take Advantage of moves in (ZYXI) - Stock Traders Daily
Zynex partners with VA to expand pain management access By Investing.com - Investing.com Canada
Zynex partners with VA to expand pain management access - Investing.com
Zynex's SWOT analysis: pain management firm's stock faces growth hurdles By Investing.com - Investing.com Canada
Zynex's SWOT analysis: pain management firm's stock faces growth hurdles - Investing.com
Zynex partners with VA to offer pain management solutions for veterans - Proactive Investors
Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States (PR Newswire) - Aktiellt
Zynex partners with Veterans Affairs Medical Centers to deliver noninvasive pain relief solutions - Proactive financial news
Zynex, Inc. Sets Second Quarter 2023 Earnings Call - GuruFocus.com
Zynex Announces Completion of Its Laser Pulse Oximetry Trial - The Eastern Progress Online
Zynex CEO outlines plans for 2025 after revenue milestone – ICYMI - Proactive financial news
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters - The Malaysian Reserve
Zynex to Present at the HC Wainwright Global Investment Conference - The Eastern Progress Online
Zynex UCSF Study Results Demonstrate Laser Technology Benefits i - GuruFocus.com
Zynex study highlights precision of laser-based pulse oximeter in reducing racial bias - Proactive Investors USA
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial - MSN
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters – Company AnnouncementFT.com - Financial Times
Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates - MSN
Zynex Sets Third Quarter 2024 Earnings Call - Longview News-Journal
Zynex Inc. Achieves $200M Milestone and Sets Ambitious Goals for 2025 - Proactive Investors UK
Non Invasive Pain Management Devices Market Overall Study - openPR
Objective long/short (ZYXI) Report - Stock Traders Daily
Zynex's (ZYXI) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
CHIEF FINANCIAL OFFICER Moorhead Daniel J was granted 5,000 shares and covered exercise/tax liability with 4,879 shares, decreasing direct ownership by 42% to 35,561 units (SEC Form 4) - Quantisnow
Zynex stock retains buy rating on FDA progress - Investing.com
Zynex stock retains buy rating on FDA progress By Investing.com - Investing.com Canada
Zynex completes clinical verification trial of pulse oximeter - Yahoo Finance
Muscle Stimulator Market Next Big Thing | Major Giants- Axiobionics, Zynex, NeuroMetrix - openPR
Hotchkis & Wiley Capital Management LLC Raises Holdings in Zynex, Inc. (NASDAQ:ZYXI) - MarketBeat
Zynex completes trial for new pulse oximeter technology By Investing.com - Investing.com Canada
Laser-Based Pulse Oximeter Advances Toward FDA Submission - Sleep Review
Zynex eyes FDA submission for NiCO pulse oximeter following successful verification trial - Proactive Investors Australia
Zynex completes trial for new pulse oximeter technology - Investing.com
Zynex Completes Breakthrough Clinical Trial for Next-Gen Laser Pulse Oximeter at Duke University - StockTitan
Zynex Announces Open Oximetry Project Membership - GuruFocus.com
Zynex CFO Daniel Moorhead sells $80,800 in company stock By Investing.com - Investing.com Nigeria
Insider Sell Alert: Daniel Moorhead Sells 10,000 Shares of Zynex Inc (ZYXI) - GuruFocus.com
Zynex CFO Daniel Moorhead sells $80,800 in company stock - Investing.com
Zynex joins Open Oximetry Project as it advances innovative NiCO pulse oximeter - Proactive Investors Australia
Zynex Inc (ZYXI) 財務データ
収益
当期純利益
現金流量
EPS
Zynex Inc (ZYXI) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 14 '24 |
Sale |
8.09 |
2,000 |
16,180 |
14,603,662 |
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 12 '24 |
Sale |
9.24 |
2,000 |
18,480 |
14,607,662 |
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 07 '24 |
Sale |
9.17 |
2,000 |
18,340 |
14,613,662 |
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 11 '24 |
Sale |
9.09 |
2,000 |
18,180 |
14,609,662 |
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 08 '24 |
Sale |
8.77 |
2,000 |
17,540 |
14,611,662 |
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 13 '24 |
Sale |
8.37 |
2,000 |
16,740 |
14,605,662 |
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 06 '24 |
Sale |
8.82 |
2,000 |
17,640 |
14,615,662 |
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 04 '24 |
Sale |
8.67 |
2,000 |
17,340 |
14,619,350 |
Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 05 '24 |
Sale |
8.05 |
2,000 |
16,100 |
14,617,662 |
MOORHEAD DANIEL J | CHIEF FINANCIAL OFFICER |
Nov 01 '24 |
Sale |
8.59 |
10,000 |
85,900 |
44,878 |
大文字化:
|
ボリューム (24 時間):